KRAS-selective protein degrader (A2A Pharmaceuticals)

N/A

Report date: 2025/01/26 18:38:15
NME

Base Information

Drug NameKRAS-selective protein degrader (A2A Pharmaceuticals)
Drug Alias NameO-05
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog modulators
TargetsGTPase KRas
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesA2A Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesA2A Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A